Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
- 29 July 2010
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 128 (1), 69-78
- https://doi.org/10.1007/s10549-010-1024-7
Abstract
Antiestrogen therapies arrest susceptible estrogen receptor (ER)-positive breast cancers by increasing p27. Since Src phosphorylates p27 to promote p27 proteolysis, Src activation observed in up to 40% of ER-positive cancers may contribute to antiestrogen resistance. In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27. Saracatinib and fulvestrant together more effectively increased p27, reduced Ki67, and impaired MDA-MB-361 xenograft tumor growth in vivo than either of the drugs alone. In contrast, saracatinib monotherapy rapidly gave rise to drug resistance. Since combined ER and Src inhibition delays development of resistance in vivo, these data support further clinical investigation of saracatinib in combination with fulvestrant for women with ER-positive breast cancer. Proteomic analysis revealed striking bypass activation of the mTOR pathway in saracatinib-resistant tumors. mTORC1 activation also arose following long-term culture of ER-positive breast cancer lines in the presence of saracatinib. These data indicate the utility of proteomic analysis of drug-resistant tumors to identify potential means of drug resistance. The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.Keywords
This publication has 34 references indexed in Scilit:
- Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cellsBreast Cancer Research and Treatment, 2008
- Pharmacodynamic Markers of Perifosine EfficacyClinical Cancer Research, 2007
- Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancerJCI Insight, 2007
- Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2Cell, 2007
- Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor–positive human breast cancer cellsMolecular Cancer Therapeutics, 2006
- Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistanceThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor actionThe Journal of cell biology, 2003
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycleEuropean Journal of Cancer and Clinical Oncology, 1983